The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung

被引:5
|
作者
Bulutay, Pinar [1 ]
Firat, Pinar [1 ]
Zeren, Handan [2 ]
Erus, Suat [3 ]
Tanju, Serhan [3 ]
Dilege, Sukru [3 ]
机构
[1] Koc Univ, Med Fac, Dept Pathol, Istanbul, Turkey
[2] Acibadem Univ, Med Fac, Dept Pathol, Istanbul, Turkey
[3] Koc Univ, Med Fac, Dept Thorac Surg, Istanbul, Turkey
关键词
PD-L1; lung cancer; immunotherapy; lung adenocarcinoma; IMMUNE CELLS; EXPRESSION; CANCER; IMMUNOHISTOCHEMISTRY; CLASSIFICATION; IMMUNOTHERAPY; RELIABILITY; ANTI-PD-1; LIGANDS;
D O I
10.3906/sag-2004-61
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents. However, heterogeneous staining of PD-L1 can cause false-negative results. The aim of this study is to evaluate the importance of histological patterns on PD-L1 staining heterogeneity in lung adenocarcinomas (LAC). Materials and methods: PD-L1 immunohistochemistry (IHC) stain was performed to two different tissue cores of 128 LAC cases, and cut-off values are given for grouping the cases according to the percentage of staining (1%-10%, 11%-49%, 50%-100%). Staining rates between cores were compared and analyzed by their histological patterns. Also, the relation of the PD-L1 expression with the clinicopathological characteristics of the cases was analyzed. Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off. PD-L1 expression was significantly related to the high grade micropapillary and solid patterns of adenocarcinomas (p:0.01). Staining cut-offs were mostly similar between cores (43/50, 86%) (k:0.843). However, 14% of them were positive only in one core (7 of 50). This false negativity was mostly related to the histological patterns. Conclusion: Our data reveal the heterogeneous staining of PD-L1 expression, also micropapillary and solid patterns show higher rates of PDL expression. Therewithal, these findings also highlight the importance of taking into consideration of histological patterns, when choosing a paraffin block for the PDL1.
引用
收藏
页码:204 / 213
页数:10
相关论文
共 50 条
  • [31] Comprehensive Assessment of PD-L1 Staining Heterogeneity and Expression by Histologic Pattern in Pulmonary Adenocarcinomas: Clinical Implications
    Gagne, Andreanne
    Enlow, William
    Pigeon, Marc-Antoine
    Orain, Michele
    Turcotte, Stephane
    Joubert, Philippe
    MODERN PATHOLOGY, 2017, 30 : 478A - 478A
  • [32] Discordant genomic correlates of PD-L1 expression in lung adenocarcinoma among multiple cohorts using dissimilar PD-L1 testing techniques
    Jiao, X.
    Qin, B.
    Xu, Y.
    Gong, F.
    Zang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1113 - S1113
  • [33] Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas
    Zito Marino, Federica
    Rossi, Giulio
    Montella, Marco
    Botti, Gerardo
    De Cecio, Rossella
    Morabito, Alessandro
    La Manna, Carmine
    Ronchi, Andrea
    Micheli, Mariacarolina
    Salatiello, Giuseppe
    Micheli, Pietro
    Rocco, Danilo
    Accardo, Marina
    Franco, Renato
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2020, 44 (03) : 378 - 386
  • [34] Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples
    Casadevall, David
    Clave, Sergi
    Taus, Alvaro
    Hardy-Werbin, Max
    Rocha, Pedro
    Lorenzo, Marta
    Menendez, Silvia
    Salido, Marta
    Albanell, Joan
    Pijuan, Lara
    Arriola, Edurne
    CLINICAL LUNG CANCER, 2017, 18 (06) : 682 - +
  • [35] PD-L1 Testing On NSCLC Cytology Samples in a UK Teaching Hospital
    Al-Najjar, H.
    Nadira, N.
    Higgins, C.
    Thiryayi, S.
    Shelton, D.
    Bailey, S.
    Rana, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S549 - S550
  • [36] Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples
    Boothman, A.
    Scott, M.
    Ratcliffe, M.
    Whiteley, J.
    Dennis, P.
    Wadsworth, C.
    Sharpe, A.
    Rizvi, N.
    Garassino, M.
    Walker, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S422 - S422
  • [37] Heterogeneity and Geographical Patterns of PD-L1 Positive Tumor Infiltrating Immune Cells in Colonic Adenocarcinoma
    Messersmith, L.
    Williams, G.
    Broadwater, D. R.
    Brady, R.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 : S156 - S156
  • [38] PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung
    Damotte, D.
    Charpentier, M. C.
    Bernardi, M.
    Watkin, E.
    Versini, I. Goubin
    Lamy, R.
    Piton, N.
    Geriniere, L.
    Forest, F.
    Gervais, R.
    Monnet, I.
    Madrosyk, A.
    Guisier, F.
    Serrand, C.
    Genty, C. Locher
    Decroisette, C.
    Auliac, J. B.
    Jeanfaivre, T.
    Doubre, H.
    Arpin, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Discordant genomic correlates of PD-L1 expression in lung adenocarcinoma among multiple cohorts using dissimilar PD-L1 testing techniques.
    Wang, Lijie
    Liu, Siyao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Will Testing for Tumor Mutational Burden Bring the Same Challenges as Testing for PD-L1?
    Gupta V.
    Ramirez M.C.
    Schauser L.
    Genetic Engineering and Biotechnology News, 2019, 39 (06): : 56 - 57